SC 13G: Autolus Therapeutics plc
Ticker: AUTL · Form: SC 13G · Filed: 2024-11-12T00:00:00.000Z
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Autolus Therapeutics plc.
Risk Assessment
Risk Level: low
From the Filing
0000315066-24-002670.txt : 20241112 0000315066-24-002670.hdr.sgml : 20241112 20241112095012 ACCESSION NUMBER: 0000315066-24-002670 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20241112 DATE AS OF CHANGE: 20241112 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-90550 FILM NUMBER: 241444438 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: FMR LLC CENTRAL INDEX KEY: 0000315066 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] ORGANIZATION NAME: IRS NUMBER: 043532603 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6175706339 MAIL ADDRESS: STREET 1: 245 SUMMER STREET CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: FMR CORP DATE OF NAME CHANGE: 19920717 SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 AUTOLUS THERAPEUTICS PLC COMMON STOCK Cusip #05280R100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #05280R100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 17,773,873 Item 6: 0 Item 7: 17,773,873 Item 8: 0 Item 9: 17,773,873 Item 11: 6.679% Item 12: HC Cusip #05280R100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 17,773,873 Item 8: 0 Item 9: 17,773,873 Item 11: 6.679% Item 12: IN Item 1(a). Name of Issuer: AUTOLUS THERAPEUTICS PLC Item 1(b). Address of Issuer's Principal Executive Offices: THE MEDIAWORKS, 191 WOOD LANE LONDON, W12 7FP United Kingdom Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 05280R100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 17,773,873 (b) Percent of Class: 6.679% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 17,773,873 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of AUTOLUS THERAPEUTICS PLC. No one other person's interest in the COMMON STOCK of AUTOLUS THERAPEUTICS PLC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not app